Home > Neurology > Blood-brain-barrier therapy for CNS tumors may have lasting effect on vision

Blood-brain-barrier therapy for CNS tumors may have lasting effect on vision

Journal
JAMA Ophthalmology
Reuters Health - 10/12/2020 - Osmotic blood-brain-barrier disruption (BBBD) therapy, which increases the penetration of chemotherapeutics into malignant tumors of the central nervous system (CNS), may also affect sight, researchers say. "Osmotic blood-brain-barrier disruption for CNS tumors causes a dose-dependent maculopathy that can affect vision and progress over years even after cessation of therapy," Dr. Phoebe Lin of Oregon Health and Science University, in Portland, told Reuters Health by email. "Thus, patients undergoing treatment with this modality should be counseled and screened at baseline and at yearly intervals." Pigmentary maculopathy was first described in the 1980s in patients with primary CNS lymphoma treated with BBBD and chemotherapy, Dr. Lin and her colleagues note in JAMA Ophthalmology. Subsequent work showed that this particular maculopathy was seen only in such patients, they add. There have been no reports of such findings beyond thos...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on